中南大学学报(医学版) 2013, 38(1) 101-108 DOI: 10.3969/j.issn.1672-7347.2013.01.019 ISSN: 1672-7347 CN: 43-1427/R

综述

调脂药物的作用靶点

李慧, 景贤, 邓晓兰, 欧阳冬生

中南大学临床药理研究所, 湖南省药理学重点实验室, 长沙410078

摘要： 血脂异常是动脉粥样硬化、冠心病等心血管疾病的重要危险因素, 调脂药物治疗的主要目标是降低血浆低密度脂蛋白, 升高高密度脂蛋白。尼曼- 匹克C1 型类似蛋白1(NPC1L1), 胆固醇酰基转移酶(ACAT), 三磷酸腺苷结合盒转运体G5 和G8(ABCG5/G8), 微粒体三酰甘油转运蛋白(MTP), 单酰基甘油酰基转移酶(MAGT), 二酰基甘油酰基转移酶(DAGT), 过氧化物酶体增生激活型受体(PPAR), 法尼醇X 受体(FXR), 前蛋白转化酶枯草溶菌素9(PCSK9) 等是参与血脂代谢的重要蛋白, 也是调脂药物作用相关的靶点, 在调脂药物的开发和临床用药选择上具有重要参考价值。

关键词： 高脂血症 胆固醇 三酰甘油 动脉粥样硬化

Targets of anti-hyperlipidemia drugs

LI Hui, JING Xian, DENG Xiaolan, OUYANG Dongsheng

Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China

Abstract: Hyperlipidemia is one of the most important risk factors for atherosclerosis, coronary heart disease and other cardiovascular diseases. It is the main effect of lipid-lowering drugs to reduce the plasma low-density lipoprotein or to enhance high-density lipoprotein. Niemann-Pick C1 like 1 protein (NPC1L1), acyl-coenzyme A: cholesterol acyltransferases (ACAT), ATP binding cassette transporter G member 5 and member 8 (ABCG5/G8), microsomal triglyceride transfer protein (MTP), monoacylglycerol acyltransferase, diacylglycerol acyltransferases (MAGT), peroxisome proliferator-activated receptor (PPAR), farnesoid X receptor (FXR), and proprotein convertase subtilisin/kexin type 9 (PCSK9) play key roles in the metabolism of lipid, which are regarded as the targets of anti-hyperlipidemia drugs and evidence for clinic choice of lipid-lowering drugs. These proteins are considered as breakthrough points for new lipid-lowering drug development.

Keywords: hyperlipidemia cholesterol triglyceride atherosclerosis

收稿日期 2012-04-12 修回日期 网络版发布日期

DOI: 10.3969/j.issn.1672-7347.2013.01.019

基金项目:

“十二五”国家科技支撑计划(SQ2010BAJY1411-08);国家“重大新药创制”科技重大专项(2012ZX09303014-001)。

通讯作者: 欧阳冬生, Email: ouyangyj@163.com

作者简介: 李慧, 硕士研究生, 主要从事心血管药理学方面的研究。

作者Email: ouyangyj@163.com

参考文献：

1. Schober SE, Carroll MD, Lacher DA, et al. High serum totalcholesterol--an indicator for

monitoring cholesterol lowering efforts:U.S. adults, 2005-2006 [J] . NCHS Data Brief, 2007, 2: 1-8.
2. Sudhop T, Lütjohann D, von Bergmann K. Sterol transporters: targetsof natural sterols and new lipid lowering drugs [J] . Pharmacol Ther,2005, 105(3): 333-341.
3. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acidreceptors in metabolic regulation [J] . Physiol Rev, 2009, 89(1): 147-191.
4. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like1(NPC1L1) is the intestinal phytosterol and cholesterol transporterand a key modulator of whole-body cholesterol homeostasis [J] . J BiolChem, 2004, 297(32): 33586-33592.
5. Dikkers A, Tietge UJ. Biliary cholesterol secretion: more than a simpleABC [J] . World J Gastroenterol, 2010, 16(47): 5936-5945.
6. Yu L, Li-Hawkins J, Hammer RE, et al. Overexpression of ABCG5 andABCG8 promotes biliary cholesterol secretion and reduces fractionalabsorption of dietary cholesterol [J] . Clin Invest, 2002, 110(5): 671-680.
7. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters,atherosclerosis and inflammation [J] . Atherosclerosis, 2010, 211(2):361-370.
8. Chang TY, Chang C. Ezetimibe blocks internalization of the NPC1L1/cholesterol complex [J] . Cell Metab, 2008, 7(6): 469-471.
9. Rozman D, Monostory K. Perspectives of the non-statin hypolipidemicagents [J] . Pharmacol Ther, 2010, 127(1): 19-40.
10. Ja in KS, Kul k arni RR, Ja in DP. Cur rent dr ug target s forantihyperlipidemic therapy [J] . Mini Rev Med Chem, 2010, 10(3):232-262.
11. Smith S. The animal fatty acid synthase: one gene, one polypeptide,seven enzymes [J] . FASEB J, 1994, 8(15): 1248-1259.
12. Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functionalroles of MGAT and DGAT enzymes in energy metabolism [J] . Am JPhysiol Endocrinol Metab, 2009, 297(1): E10-18.
13. Peng LF, Schaefer EA, Maloof N, et al. Ceestatin, a novel smallmolecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase [J] . J Infect Dis, 2011, 204(4):609-616.
14. Stein EA, Bays H, O'Br ien D, et al. Lapaqui stat acetate:development of a squalene synthase inhibitor for the treatment ofhypercholesterolemia [J] . Circulation, 2011, 123(18): 1974-1985.
15. Petranyi G, Ryder NS, Stütz A. Allylamine derivatives: new class ofsynthetic antifungal agents inhibiting fungal squalene epoxidase [J] .Science,1984, 224(4654): 1239-1241.
16. Thupari JN, Landree LE, Ronnett GV, et al. C75 increases peripheralenergy utilization and fatty acid oxidation in diet-induced obesity [J] .Proc Natl Acad Sci USA, 2002, 99(14): 9498-502.
17. King AJ, Segreti JA, Larson KJ, et al. Diacylglycerol acyltransferase 1inhibition lowers serum triglycerides in the Zucker fatty rat and thehyperlipidemic hamster [J] . J Pharmacol Exp Ther, 2009, 330(2): 526-531.
18. Li T, Matozel M, Boehme S, et al. Overexpression of cholesterol 7a-hydroxylase promotes hepatic bile acid synthesis and secretion andmaintains cholesterol homeostasis [J] . Hepatology, 2011, 53(3): 997-1006.
19. Kitayama K, Nakai D, Kono K, et al. Novel non-systemic inhibitorof ileal apical Na+-dependent bile acid transporter reduces serumcholesterol levels in hamsters and monkeys [J] . Eur J Pharmacol, 2006,539(1/2): 89-98.
20. Stein O, Stein Y. Lipid transfer proteins(LTP) and atherosclerosis [J] .Atherosclerosis, 2005, 178(2): 217-230.
21. Ikonen E. Mechanisms for cellular cholesterol transport: defects andhuman disease [J] . Physiol Rev, 2006, 86(4): 1237-1261.
22. Niot I, Poirier H, Tran TT, et al. Intestinal absorption of long-chain fatty acids:evidence and uncertainties [J] . Prog Lipid Res, 2009, 48(2): 101-115.
23. Xie Y, Newberry EP, Young SG, et al. Compensatory Increase inhepatic lipogenesis in mice with conditional intestine-specific MttpDeficiency [J] . J Biol Chem, 2006, 281(7): 4075-4086.
24. Lewis GF, Rader DJ. New insights into the regulation of HDLmetabolism and reverse cholesterol transport [J] . Circ Res, 2005, 96(12): 1221-1232.
25. Vedhachalam C, Duong PT, Nickel M, et al. Mechanism of ATP-bindingcassette transporter A1-mediated cellular lipid efflux to apolipoproteinA-I and formation of high density lipoprotein particles [J] . J Biol Chem,2007, 282(34): 25123-25130.

26. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations inPCSK9, low LDL, and protection against coronary heart disease [J] . NEngl J Med, 2006, 354(12): 1264-1272.
27. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 inhyperlipidemia: focus on therapeutic implications [J] . Am J CardiovascDrugs, 2011, 11(3): 145-152.
28. Ogino M, Fukui S, Nakada Y, et al. Discovery of a potent and orally available acyl-CoA: cholesterol acyltransferase inhibitor as an antiatherosclerotic agent: (4-phenylcoumarin) acetanilide derivatives [J] .Chem Pharm Bull(Tokyo), 2011, 59(10): 1268-1273.
29. Ohshiro T, Matsuda D, Nagai K, et al. The selectivity of beauveriolidederivatives in inhibition toward the two isozymes of acyl-CoA:cholesterol acyltransferase [J] . Chem Pharm Bull, 2009, 57(4): 377-381.
30. Tardif JC, Grégoire J, L'Allier PL, et al. Effects of the acyl coenzymeA:cholesterol acyltransferase inhibitor avasimibe on humanatherosclerotic lesions [J] . Circulation, 2004, 110(21): 3372-3377.
31. Meuwese MC, de Groot E, Duivenvoorden R, et al. ACAT inhibitionand progression of carotid atherosclerosis in patients with familialhypercholesterolemia: the CAPTIVATE randomized trial [J] . JAMA,2009, 301(11): 1131-1139.
32. Rizzo M. Lomitapide, a microsomal triglyceride transfer proteininhibitor for the treatment of hypercholesterolemia [J] . IDrugs, 2010,13(2): 103-111.
33. Wren JA, Gossellin J, Sunderland SJ. Dirlotapide: a review of itsproperties and role in the management of obesity in dogs [J] . J VetPharmacol Ther, 2007, 30(suppl 1): 11-16.
34. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoproteinB synthesis inhibitor, for lowering of LDL cholesterol concentrationsin patients with homozygous familial hypercholesterolaemia: arandomised, double-blind, placebo-controlled trial [J] . Lancet, 2010,375(9719): 998-1006.
35. Burgess JW, Boucher J, Neville TA, et al. Phosphatidylinositol promotescholesterol transport and excretion [J] . J Lipid Res, 2003, 44(7): 1355-1563.
36. Devaraj S, Jialal I. Novel Cholesteryl ester transfer protein Inhibitors:promising therapy for dyslipidemia [J] . Metab Syndr Relat Disord,2011, 9(3): 163-165.
37. Lindholm MW, Elmén J, Fisker N, et al. PCSK9 LNA antisenseoligonucleotides induce sustained reduction of LDL cholesterol innonhuman primates [J] . Mol Ther, 2012, 20(2): 376-381.
38. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with orwithout an antibody to PCSK9 in primary hypercholesterolemia [J] . NEngl J Med, 2012, 367(20): 1891-1900.
39. Cariou B, Staels B. FXR: a promising target for the metabolicsyndrome [J] . Trends Pharmacol Sci, 2007, 28(5): 236-243.
40. Guo GL, Santamarina Fojo S, Akiyama TE, et al. Effects of FXR infoam-cell formation and atherosclerosis development [J] . BiochimBiophys Acta, 2006, 1761(12): 1401-1409.
41. Bilz S, Samuel V, Morino K, et al. Activation of the farnesoid X receptorimproves lipid metabolism in combined hyperlipidemic hamsters [J] .Am J Physiol Endocrinol Metab, 2006, 290(4): E716-E722.
42. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions ofperoxisome proliferator-activated receptors in lipid metabolism andatherosclerosis [J] . Arterioscler Thromb Vasc Biol, 2002, 22(5): 717-726.
43. Kida K, Nakajima M, Mohri T, et al. Kida K, Nakajima M, Mohri T,et al. PPARα is regulated by miR-21 and miR-27b in human liver [J] .Pharm Res, 2011, 28(10): 2467-2476.
44. Mogilenko DA, Shavva VS, Dizhe EB, et al. PPARγ activates ABCA1gene transcription but reduces the level of ABCA1 protein in HepG2cells [J] . Biochem Biophys Res Commun, 2010, 402(3): 477-482.
45. Barter PJ, Rye KA. Is there a role for fibrates in the management ofdyslipidemia in the metabolic syndrome? [J] . Arterioscler Thromb VascBiol, 2008, 28(1): 39-46.
46. Betteridge DJ. Effects of pioglitazone on lipid and lipoproteinmetabolism [J] . Diabetes Obes Metab, 2007, 9(9): 640-647.
47. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters,atherosclerosis and inflammation [J] . Atherosclerosis, 2011, 211(2):361-370.
48. Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, et al. Liver Xreceptors (LXRs). Part I: structure, function, regulation of activity, androle in lipid metabolism [J] . Postepy Hig Med Dosw(online), 2007, 61:736-759.
49. Ose L, Budinski D, Hounslow N, et al. Long-term treatment withpitavastatin is effective and well tolerated by patients with primaryhypercholesterolemia or combined dyslipidemia [J] . Atherosclerosis,2010, 210(1): 202-208.
50. Matralis AN, Katselou MG, Nikitakis A, et al. Novel benzoxazineand benzothiazine

derivatives as multifunctional antihyperlipidemicagents［J］. J Med Chem, 2011, 54(15): 5583-5591.
51. Vu CB, Milne JC, Carney DP, et al. Discovery of benzothiazolederivatives as efficacious and enterocyte-specific MTP inhibitors［J］.Bioorg Med Chem Lett, 2009, 19(5): 1416-1420.
52. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitorevacetrapib administered as monotherapy or in combination withstatins on HDL and LDL cholesterol: a randomized controlled trial［J］.JAMA, 2011, 306(19): 2099-2109.
53. Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates:focus on bezafibrate［J］. Vasc Health Risk Manag, 2008, 4(1): 131-141.
本刊中的类似文章